Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
Key Highlights
- ➤BASECAMP enrollment completed, surpassing target in less than nine months
- ➤Topline BASECAMP clinical data now expected in first quarter of 2027
- ➤Forazapadin tested at 60 mg, 120 mg and placebo in 1:1:1 randomization
- ➤BASECAMP enrolled ambulatory boys aged 7 to 10 across 18 global sites
Expert Statements
Frank Gleeson, Co-founder and Chief Executive Officer of Satellos
“We are thrilled to announce that we have met and surpassed our enrollment target in BASECAMP in less than nine months from screening our first participant, reflecting the strong execution of our clinical program”
Frank Gleeson, Co-founder and Chief Executive Officer of Satellos
“We believe BASECAMP could support discussions with the FDA regarding a potential accelerated development pathway for forazapadin”
Frank Gleeson, Co-founder and Chief Executive Officer of Satellos
“Given the significance and proximity of this opportunity, we believe it is important to be thoughtful and transparent in how we develop and communicate the results from the trial”
Frank Gleeson, Co-founder and Chief Executive Officer of Satellos
“We have therefore decided to take the time necessary to compile the most complete dataset possible. Accordingly, we are adjusting our previous plan for releasing data and now intend to share topline clinical data in the first quarter of 2027”
Wildon Farwell, M.D., Chief Medical Officer of Satellos
“The enthusiasm and commitment of the Duchenne community have enabled us to exceed our enrollment target and build a robust global study”
Wildon Farwell, M.D., Chief Medical Officer of Satellos
“With multiple dose cohorts and a broad range of clinical, functional and biomarker assessments, we believe BASECAMP can generate a substantial body of data that we expect to help us better understand forazapadin, its potential as a novel treatment for Duchenne, and guide us in determining a potential path to approval”
Wildon Farwell, M.D., Chief Medical Officer of Satellos
“We are deeply grateful to the patients and families who have made this research possible”
TORONTO, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced that enrollment has been completed for BASECAMP, the company’s Phase 2 clinical trial evaluating forazapadin for the treatment of Duchenne muscular dystrophy (DMD) in ambulatory boys 7 to 10 years of age. Forazapadin is an orally administered, small molecule drug candidate designed to restore muscle regeneration in people living with DMD, facioscapulohumeral muscular dystrophy (FSHD) and potentially other degenerative muscle diseases.
“We are thrilled to announce that we have met and surpassed our enrollment target in BASECAMP in less than nine months from screening our first participant, reflecting the strong execution of our clinical program,” said Frank Gleeson, co-founder and chief executive officer of Satellos. “We believe BASECAMP could support discussions with the FDA regarding a potential accelerated development pathway for forazapadin. Given the significance and proximity of this opportunity, we believe it is important to be thoughtful and transparent in how we develop and communicate the results from the trial. We have therefore decided to take the time necessary to compile the most complete dataset possible. Accordingly, we are adjusting our previous plan for releasing data and now intend to share topline clinical data in the first quarter of 2027.”
Get started
Create a free account to read the full story.